These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34454892)

  • 1. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.
    Triviño-Ibáñez EM; Pardo Moreno P; Ciampi Dopazo JJ; Ramos-Font C; Ruiz Villaverde G; González-Flores E; Navarro Vergara PF; Rashki M; Gómez-Río M; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):231-238. PubMed ID: 34454892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.
    Triviño-Ibáñez EM; Pardo Moreno P; Ciampi Dopazo JJ; Ramos-Font C; Ruiz Villaverde G; González-Flores E; Navarro Vergara PF; Rashki M; Gómez-Río M; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Jul; ():. PubMed ID: 34294586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and Toxicities after
    Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
    Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study.
    Topcuoglu OM; Orhan T; Gormez A; Alan N
    Br J Radiol; 2024 Jun; 97(1159):1255-1260. PubMed ID: 38730551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of results after 112 radioembolizations with
    Casáns-Tormo I; Guijarro-Rosaleny J; Lluch-García P; Rodríguez-Parra H; Roselló-Keränen S; Asensio-Valero L
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(4):255-264. PubMed ID: 37269983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
    Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
    J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    Mulcahy MF; Mahvash A; Pracht M; Montazeri AH; Bandula S; Martin RCG; Herrmann K; Brown E; Zuckerman D; Wilson G; Kim TY; Weaver A; Ross P; Harris WP; Graham J; Mills J; Yubero Esteban A; Johnson MS; Sofocleous CT; Padia SA; Lewandowski RJ; Garin E; Sinclair P; Salem R;
    J Clin Oncol; 2021 Dec; 39(35):3897-3907. PubMed ID: 34541864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison.
    Agirrezabal I; Bouattour M; Pinato DJ; D'Alessio A; Brennan VK; Carion PL; Shergill S; Amoury N; Vilgrain V
    Eur J Cancer; 2024 Jan; 196():113427. PubMed ID: 37988840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).
    Quartuccio N; Ialuna S; Scalisi D; D'Amato F; Barcellona MR; Bavetta MG; Fusco G; Bronte E; Musso E; Bronte F; Picciotto V; Carroccio A; Verderame F; Malizia G; Cistaro A; La Gattuta F; Moreci AM
    Curr Oncol; 2024 Mar; 31(3):1504-1514. PubMed ID: 38534947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases.
    Morsbach F; Pfammatter T; Reiner CS; Fischer MA; Sah BR; Winklhofer S; Klotz E; Frauenfelder T; Knuth A; Seifert B; Schaefer N; Alkadhi H
    Invest Radiol; 2013 Nov; 48(11):787-94. PubMed ID: 23748229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
    Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma.
    Sarwar A; Ali A; Ljuboja D; Weinstein JL; Shenoy-Bhangle AS; Nasser IA; Morrow MK; Faintuch S; Curry MP; Bullock AJ; Ahmed M
    J Vasc Interv Radiol; 2021 Nov; 32(11):1560-1568. PubMed ID: 34454031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma.
    Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B
    Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal patient selection for yttrium-90 glass plus chemotherapy in the treatment of colorectal liver metastases: additional quality of life, efficacy, and safety analyses from the EPOCH study.
    Salem R; Garin E; Boucher E; Fowers K; Lam M; Padia S; Harris W
    Oncologist; 2024 Jul; ():. PubMed ID: 38985849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.